The thinking behind the Phase Forward purchase of Waban Software. more...

Exco InTouch discusses Pfizer’s endorsement, and the use of its technology in a new type of project. more...

Feasibility studies are becoming more accepted, but misconceptions may also be proliferating. Thoughts from MDS Pharma. more...

Two authors from ClinPhone consider how electronic data capture can facilitate adaptive trials. more...

How should the industry be working with drug safety data? SAS recommends more data sources and more consistency. more...

Two leading firms, Tessella and United Biosource, discuss the perception that regulators are trying to slow down the adoption of adaptive designs. more...

A biostatician with deep NIH and FDA ties talks about general guidelines for changing primary end points. Plus, the M-word. more...

Inspired by Web 2.0 tools that foster sharing and collaboration, Insightful Software released new software to generate charts and graphs in a regulated setting. more...

A Japanese pharma talks about patient diaries and biostatistical concerns. more...

Could the best-laid plans for adaptive trials have unexpected results? more...

United BioSource talks about resources (its own and others) for adaptive trials. more...

Clinical sites have it rough, and numbers from the Tufts Center for Drug Development show few heartening trends. more...

Cytel and Tourtellotte Consulting join forces to design trials and drug supply needs for adaptive protocols. more...

As life science organizations consider adaptive clinical trial designs, the process, technology and operational aspects are complex. What to consider. more...

Can your clinical data warehouse combine genotyping data, clinical data and demographic data? And analyze it in a reproducible way? A conversation with Waban. more...

Cytel and Tourtellotte consulting have integrated two important applications. more...